FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to psychiatry, and can be used in predicting visceral obesity in patients with schizophrenia receiving quetiapine treatment. To do this, an anthropometric survey is performed to determine the Tanner index. With Tanner index of more than 93.5 predict development of visceral obesity.
EFFECT: method provides timely detection of the risk of visceral obesity in this category of patients, which allows to correct antipsychotic therapy and improve the quality of treatment in general.
1 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF METABOLIC SYNDROME DEVELOPMENT IN SCHIZOPHRENIC PATIENTS RECEIVING ANTIPSYCHOTIC THERAPY | 2018 |
|
RU2703424C1 |
| METHOD OF PREDICTING RISK OF DEVELOPING HYPERPROLACTINEMIA IN WOMEN WITH SCHIZOPHRENIA TAKING ANTIPSYCHOTIC THERAPY | 2023 |
|
RU2810398C1 |
| METHOD FOR SUPPORTING MEDICAL DECISIONS ON SELECTION OF ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA IN ORDER TO PREVENT AKATHISIA | 2021 |
|
RU2756614C1 |
| DIAGNOSTIC TECHNIQUE FOR METABOLIC SYNDROME IN SCHIZOPHRENIC PATIENTS RECEIVING NEUROLEPTIC THERAPY | 2019 |
|
RU2717367C1 |
| METHOD FOR PREDICTION OF METABOLIC SYNDROME RISK WITH UNDERLYING ANTIPSYCHOTIC THERAPY IN SCHIZOPHRENIC PATIENTS | 2019 |
|
RU2722649C1 |
| METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATMENT OF PATIENTS WITH SCHIZOPHRENIA | 2021 |
|
RU2775440C1 |
| METHOD FOR PREDICTING NEGATIVE CLINICAL MANIFESTATIONS IN SCHIZOPHRENIA FLOW | 2001 |
|
RU2188577C1 |
| METHOD FOR PREDICTING THE EFFICIENCY OF TREATING PATIENTS WITH SCHIZOPHRENIA WITH ATYPICAL NEUROLEPTIC QUETIAPIN (SEROQUEL) | 2005 |
|
RU2289137C1 |
| METHOD FOR PREDICTING INFRINGEMENTS IN COMPLIANCE WITH THERAPY FOR FURTHER CORRECTION OF PATIENTS WITH SCIZOPHRENIA | 2016 |
|
RU2611934C1 |
| LABORATORY METHOD FOR DIAGNOSIS OF LEADING NEGATIVE SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA | 2015 |
|
RU2578957C1 |
